Sequencing of tumour cohorts has provided key insights into tumour etiology [1,2] 38 and has facilitated the development of new DNA based biomarkers for use in the 39 clinic [3]. The current paradigm for biomarker discovery involves comprehensive, 40 high-cost sequencing (usually exome or whole-genome) across moderately sized 41 cohorts, then subsequent application of cheaper, targeted sequencing for biomarker 42 detection in the clinic. This approach has yielded biomarkers that assist with 43 diagnosis [4,5], prognosis [6,7], personalised therapy selection [8,9] and clinical trial 44 stratification [10]. These biomarkers are now being internationally accepted into 45 molecular pathology as shown by a recent landmark consensus whitepaper for 46 nervous system tumour diagnosis [11] which will be incorporated into the World 47
Identification of mutations that guide therapy selection for patients with cancer is now 21 routine in many clinical centres. The majority of assays used for solid tumour 22 profiling use DNA sequencing to interrogate somatic point mutations as they are 23 relatively easy to identify and interpret. However many cancers, including high-grade 24 serous ovarian, oesophageal and small cell lung cancer, are driven by somatic 25 structural variants that are not measured by these assays. Therefore, there is 26 currently an unmet need for clinical assays that can cheaply and rapidly profile 27 structural variants in solid tumours. In this review we survey the landscape of 28 "actionable" structural variants in cancer and identify promising detection strategies 29 based on massively parallel sequencing.
Health Organization classification of glioma. 48 49 Comprehensive approaches such as whole-genome (WGS) and whole-exome 50 (WES) sequencing yield information on somatic point mutations, also known as 51 single nucleotide variants (SNVs, See Glossary), small somatic insertions/deletions 52 (INDELs) , and somatic structural variants (SVs). These approaches have the benefit 53 of identifying multiple mutations simultaneously, albeit at increased cost. However, 54 given the reality that most actionable mutations are SNVs, the majority of clinical 55 sequencing is currently performed using low-cost targeted gene panels that 56 interrogate SNVs [12] . 57 58 There are, however, many patients that will not benefit from SNV assays as their 59 cancers are characterised by high numbers of SVs rather than SNVs. Furthermore, 60 SV driven tumours may have few, if any, SNV drivers, as demonstrated by a recent 61 large-scale pan-cancer study [13] . Ciriello and colleagues analysis of 3,299 tumours 62 showed a hyperbolic relationship between the frequencies of SNVs and SVs across 63 different tumour types, potentially arising from differences in aberrant DNA repair 64 and mutagen exposure. The clinical implication of this work is that in the majority of 65 cancers the major driver mutations are either SNV or SV mutations. For common 66 cancers that are SV driven, such as high-grade serous ovarian [14] , oesophageal [15] , 67 neuroblastoma [16] , small-cell lung cancer [17] , and triple-negative breast 68 cancers [18] , the current bias for implementation of SNV based assays leaves 69 3 clinicians with very limited data for precision medicine. In addition, these tumours are 70 also enriched for loss of classical tumour suppressor genes including TP53, RB1, 71 NF1, which are not directly actionable. There is a significant opportunity to extend 72 clinical options for patients if cheaper methods for structural variant profiling can be 73 developed for wider implementation, as exemplified by the repurposing of 74 trastuzumab to treat gastric and other cancers with amplification of ERBB2 [19] . 75 76 Current state of the art in the clinic 77 Traditional cytogenetic techniques such as fluorescence in situ hybridisation (FISH) 78 have been used clinically to profile SVs in haematological cancers for over 20 79 years [20] . However, when applied to solid malignancies, these technologies suffer 80 from a number of drawbacks, the most significant being poor performance when 81 Figure 1 provides an overview of common cancer related structural variation and the 97 technologies currently available for detection. For detailed descriptions on structural 98 variant classification and aetiology we direct the reader to recent reviews [24] [25] [26] [27] . In 99 the following section we focus on cancer promoting SVs that provide strong 100 exemplars for clinical decision making. The prototypical oncogenic fusion, BCR-ABL in chronic myeloid leukaemia is the 104 result of a reciprocal translocation between chromosomes 22 and 9 causing a BCR-105 ABL fusion protein [28] . Patients with this fusion respond to the tyrosine kinase 106 inhibitor imatinib, which represents the earliest example of a rationally targeted 107 cancer therapy [29] . Subsequent studies have uncovered specific fusions across a 108 range of tumour types [30, 31] Clinical assays to identify fusions have focused on detection of known markers. 125 Break-apart FISH, where probes located at either side of the breakpoint show a 126 separation in the presence of the fusion, has been the assay of choice for clinical 127 profiling. Where fusion specific antibodies exist, IHC has been applied as a simple 128 low-cost alternative. Alternative approaches using sequencing based methods will 129 depend highly on the recurrent nature of the underlying genomic aberration and the 130 intron size of the two fused genes. If the aberration involves a loss of genetic 131 material, then the detection task is easier as the absence of exons in the fusion 132 genes is usually a good proxy for the presence of the fusion. If the aberration 133 causing the fusion is balanced, detection becomes much more difficult [38] . If there Integrating data from multiple SVs using genome-wide profiling can reveal diagnostic 226 and prognostic information which now offer clinically useful biomarkers [61] [62] [63] Other improved algorithms also make it possible to go beyond the simple binary 293 score indicating presence or absence of a given mutation-by using the allele 294 frequency of a mutation it is possible reconstruct the evolution of a tumour and 295 determine the fraction of tumour cells that contain the mutation, even for SVs [37, 81] . 296 This may have strong clinical benefits, as detecting actionable mutations that are 297 present on the trunk of the tumour phylogenetic tree rather than the branches, may 298 allow selection of therapy that targets the bulk of the tumour cells [77] . To assist in the process of therapy rationalisation, many cancer centres have 319 appointed panels of experts to decide on the best course of treatment given complex 320 molecular results [84] . These panels are typically made up of clinicians, scientists, 321 bioinformaticians and others that collectively decide if the molecular evidence is 322 sufficient to make a therapeutic intervention. While this pipeline results in a high-level 323 of care, it is ultimately low-throughput. One way to overcome this is to ensure that 324 detailed information on the decision making process of these panels is captured so 325 that areas of redundancy and automation can be identified and throughput improved. 326 One of the critical areas for achieving this improvement is enhanced annotation of 327 structural variants and the functional impact (including possible confounders). To To WGS or not to WGS 390 Since the goal of sequencing a complete genome for $1000 was realised in 2014 391 [93], there has been continuing debate on whether the time is right to adopt WGS 392 routinely in the clinic [94] . For reasons outlined above, comprehensive 393 characterisation of SVs in specific cancers would greatly benefit from routine deep 394 WGS, however, significant barriers still need to be overcome before this could be 395 considered feasible. These include a reduction in the high human costs associated 396 with computational analysis, functional interpretation, and identification of actionable 397 13 drivers. Developing strategies to overcome these challenges is currently uninformed 398 as there are no studies that have directly assessed the clinical benefit of whole-399 genome sequencing in cancer although many major cancer centres are starting to 400 grapple with the significant infrastructure required for clinical WGS. In addition, 401 several national and regional WGS sequencing efforts are underway that may aberrations, that involve changes in the amount of genetic material in the nucleus. 878 The technologies listed that interrogate all of these aberrations in a clinical setting 879 involve a trade-off between cost, resolution, comprehensiveness, and applicability to 880 formalin-fixed clinical samples. (Reviewed in [25, 84, 105] .)
